LION Bioscience AG Overwhelming Majority Of Shareholders Approves The Repositioning Of The Company

Heidelberg, 29 November 2006 – The Shareholders of LION bioscience AG attended the company’s Annual General Meeting on 28 November 2006 with a total capital of more than 54 percent and expressed their strong interests in the future of the company. An overwhelming majority of more than 99 percent approved all proposals of the management and supervisory board. The key resolutions related to the generation of authorised and conditional capital, the extension of the supervisory board and the change of the company’s name. With renaming into SYGNIS Pharma AG the repositioning of the company will be made visible to the public.